News
FATE
--
0.00%
--
BRIEF- Fate Therapeutics Reports Publication of FT538 Preclinical Data
reuters.com · 09/15 12:07
Fate Therapeutics Announces Publication Of FT538 Preclinical Data Demonstrating Enhanced Serial Killing And Functional Persistence Without Cytokine Support
 Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced today the publication of
Benzinga · 09/15 12:04
Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support
Peer-Reviewed Cell Stem Cell Publication Highlights Shared Metabolic, Transcriptional, and Functional Features of FT538 and Adaptive NK CellsSAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceu...
GlobeNewswire · 09/15 12:00
Insider Sell: Fate Therapeutics
MT Newswires · 09/14 16:18
Cathie Wood Makes Adjustments to Portfolio in August
GuruFocus News · 09/13 15:47
2 Stocks in Cathie Wood�s ARK innovation Fund Wall Street Predicts Will Rally by 40%
StockNews.com · 09/09 15:51
Cathie Wood's ARK Invest Posts Fund Purchases For Wednesday, Sept. 8, 2021: PATH, NVTA, FATE, PD, DE, MKFG, KMTUY, SPFR, ROKU, SPLK, KVSB, ADPT, SLGC, VCYT, PSNL, RPTX, ETSY, FTCH, STNE, Z, JD, HEI, BLDE, AVAV
UiPath (PATH) - 1,382,967 Shares Invitae (NVTA) - 616,413 Fate Therapeutics (FATE) - 129,739 PagerDuty (PD) - 55,058 Deere & Co (DE) - 37,991 Markforged (MKFG) - 600,664 Komatsu (KMTUY) - 96,118 Jaws
Benzinga · 09/09 13:58
Why Is Fate Therapeutics (FATE) Down 21% Since Last Earnings Report?
Zacks.com · 09/03 15:31
Cathie Wood's ARK Invest Posts Fund Purchases For Thursday, Sept. 2, 2021: FATE, KMTUY, BLDE, MKFG, NNDM, KTOS, NIU, SPFR, GENI, VEEV, PFE, NVTA, PSNL, JD, PDD, Z, TDOC, PRNT
Fate Therapeutics (FATE) - 148,263 Shares Komatsu (KMTUY) - 189,578 Blade Air Mobility (BLDE) - 370,118 Markforged (MKFG) - 259,540 Nano Dimension (NNDM) - 197,145 Kratos Defense & Security Solutions (KTOS) -
Benzinga · 09/03 13:14
Fate Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will present a...
GlobeNewswire · 09/02 20:01
Cathie Wood's ARK Invest Posts Fund Purchases For Monday, Aug. 30, 2021: SGFY, FATE, VCYT, ACIC, DDD, NNDM, MKFG, KTOS, NIU, BLDE, SPFR, PTON, GENI, PFE, NVTA, DYNS, QSI, ADPT, PSNL, RPTX
Signify Health (SGFY) - 418,845 Fate Therapeutics (FATE) - 89,825 Veracyte (VCYT) - 3,391 Atlas Crest Investment Corp (ACIC) - 860,704 3D Systems (DDD) - 138,600 Nano Dimensions (NNDM)
Benzinga · 08/31 14:56
Integral Health Asset Management, LLC Buys Anthem Inc, Biogen Inc, Regeneron Pharmaceuticals ...
GuruFocus News · 08/30 16:38
Cathie Wood's ARK Invest Posts Fund Purchases For Friday, Aug. 27, 2021: FATE, SGFY, ACIC, KTOS, GENI, PFE, DYNS, RPTX, PSNL, ADPT, QSI, PDD, JD, TDOC, PRNT
Fate Therapeutics (FATE) - 172,458 Signify Health (SGFY) - 190,400  Atlas Crest Investment Corp (ACIC) - 190,900  Kratos Defense & Security Solutions (KTOS) - 59,400  Genius Sports
Benzinga · 08/30 14:39
Endurant Capital Management LP Buys Cigna Corp, Icon PLC, Thermo Fisher Scientific Inc, Sells ...
GuruFocus News · 08/27 16:38
Morgan Stanley Initiates Coverage On Fate Therapeutics with Equal-Weight Rating, Announces Price Target of $77
Morgan Stanley analyst Michael Ulz initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight rating and announces Price Target of $77.
Benzinga · 08/26 11:57
We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, Fate Therapeutics...
Simply Wall St. · 08/26 11:36
Cathie Wood's ARK Invest Posts Fund Purchases For Tuesday, Aug. 24, 2021: DKNG, FATE, SRNG, SGFY, NVTA, KTOS, MKFG, DDD, KMTUY, SPFR, GENI, LPSN, PFE, ADPT, QSI, PSNL, MASS, CMIIU, RPTX, DYNS, Z, TDOC, COIN, PDD, PRNT, ACIC
DraftKings (DKNG) - 1,073,171 Shares Fate Therapeutics (FATE) - 529,348 Soaring Eagle Acquisition (SRNG) - 1,197,532 Signify Health (SGFY) - 205,551 Invitae (NVTA) - 49,322 Kratos Defense & Security
Benzinga · 08/25 13:19
Sphera Funds Management Ltd. Buys Xenon Pharmaceuticals Inc, C4 Therapeutics Inc, Werewolf ...
GuruFocus News · 08/24 22:38
Lisanti Capital Growth, LLC Buys Asana Inc, Lattice Semiconductor Corp, Brooks Automation Inc, ...
GuruFocus News · 08/24 15:38
Copernicus Capital Management, LLC Buys Vertex Pharmaceuticals Inc, Atara Biotherapeutics Inc, ...
GuruFocus News · 08/23 22:38
Webull provides a variety of real-time FATE stock news. You can receive the latest news about Fate through multiple platforms. This information may help you make smarter investment decisions.
About FATE
Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.